China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced a new cooperation agreement with UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN), focusing on the development of a companion diagnostic (CDx). This collaboration builds upon a global strategic master collaboration agreement that was first signed at the end of 2021.
Development of Human 10 Gene Mutation Joint Detection Kit as a CDx for Enhertu
According to the latest agreement, AmoyDx will develop its human 10 gene mutation joint detection kit, which utilizes reversible end termination sequencing, as a CDx for AstraZeneca’s Enhertu (trastuzumab deruxtecan). Enhertu is a HER2-targeted antibody-drug conjugate (ADC) that was co-developed by AstraZeneca and Daiichi Sankyo. The CDx will be used to screen non-small cell lung cancer (NSCLC) patients for HER2 (ERBB2) mutations, providing a targeted approach to treatment.
Enhertu’s Approvals and Availability in Oncology Treatments
Enhertu has received approval to treat breast cancer in China and is available for the treatment of gastric cancer and NSCLC in other countries. The development of a companion diagnostic to identify patients who may benefit from Enhertu’s targeted therapy is a significant step forward in personalized medicine and oncology treatment.-Fineline Info & Tech
